Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,884,435 papers from all fields of science
Search
Sign In
Create Free Account
IFNL1 gene
Known as:
INTERLEUKIN 29
, IL29
, IL-29
Expand
This gene plays a role in both the antiviral response and signaling.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Antiviral Response
Cytokine Receptor Binding
Cytokine Signaling
IFNL2 gene
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Association Between IL28B, IL29 Gene Polymorphisms and Clinical Manifestations of Behçet’s Disease
G. Cakmak Genc
,
S. Karakaş Çelik
,
A. Kocaaga
,
R. Koca
,
A. Dursun
Immunological Investigations
2020
Corpus ID: 220469064
ABSTRACT Background Behçet’s disease (BD) is a chronic, multisystemic, inflammatory disease characterized by relapsing episodes…
Expand
2020
2020
Influenza-Induced Interferon Lambda Response Is Associated With Longer Time to Delivery Among Pregnant Kenyan Women
C. Seiler
,
N. Bayless
,
+8 authors
C. Blish
Frontiers in Immunology
2020
Corpus ID: 212726276
Specific causes of preterm birth remain unclear. Several recent studies have suggested that immune changes during pregnancy are…
Expand
2019
2019
Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury.
H. El Aggan
,
N. Farahat
,
N. E. El Deeb
,
A. Zeid
,
Assem El-Shendidi
Microbial Pathogenesis
2019
Corpus ID: 88467931
2018
2018
Interleukin 29 activates expression of tissue inhibitor of metalloproteinase 1 in macrophages via toll‑like receptor 2.
Haoqiang Zhang
,
B. Song
,
Shaoheng He
Molecular Medicine Reports
2018
Corpus ID: 4883287
Obesity and diabetes are characterized by low grade chronic inflammation status and insulin resistance in adipose tissue…
Expand
2016
2016
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV‐infected patients regardless of DPP4 activity
S. Johansson
,
W. Talloen
,
+4 authors
J. Aerssens
Liver international (Print)
2016
Corpus ID: 25216830
Sustained virological response (SVR) following peginterferon (pegIFN) and ribavirin (RBV) treatment in hepatitis C virus (HCV…
Expand
2016
2016
Title Human H 7 N 9 virus induces a more pronounced pro-inflammatory cytokine but an attenuated interferon response in human bronchial epithelial cells when compared with an epidemiologically-linked…
K. To
,
C. C. Lau
,
+6 authors
K. Yuen
2016
Corpus ID: 84177594
Background: Avian influenza virus H7N9 has jumped species barrier, causing sporadic human infections since 2013. We have…
Expand
2015
2015
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype–genotype correlation study
Mazen Noureddin
,
Y. Rotman
,
+4 authors
T. Liang
Genes and Immunity
2015
Corpus ID: 19434862
IFNL4 is linked to hepatitis C virus treatment response and type III interferons (IFNs). We studied the functional associations…
Expand
2015
2015
IFNL3 Genotype is associated with Differential Induction of IFNL3 in Primary Human Hepatocytes
F. Kurbanov
,
Yonghak Kim
,
+9 authors
A. Balagopal
Antiviral Therapy
2015
Corpus ID: 27160350
Background Lambda interferons (IFNLs) have potent antiviral activity against HCV, and polymorphisms within the IFNL gene cluster…
Expand
2014
2014
Regulation of interferon lambda-1 (IFNL1/IFN-λ1/IL-29) expression in human colon epithelial cells.
Adam Swider
,
R. Siegel
,
J. Eskdale
,
G. Gallagher
Cytokine
2014
Corpus ID: 207068547
2009
2009
Pharmacogenetics: A SNP for hepatitis C treatment failure
C. V. Ooij
Nature reviews genetics
2009
Corpus ID: 41260815
between variants in the interleukin-28B (IL28B) gene and lack of response to treatment for hepatitis C virus (HCV) infection…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE